The largest self-reported gut health dataset from India — collected through TumGard's five digital assessment tools between 2023 and 2026.
India has a silent gut health crisis. The TumGard India Gut Health Report 2026 — based on 20,363 self-reported responses across five digital assessment instruments — found that 82% of Indians experience acidity or heartburn, and 38% experience it every single day. Of those who underwent endoscopy, 62% tested positive for H. pylori infection, yet only 1.4% of all 13,536 survey respondents self-identified as having H. pylori — a 44x gap between perceived and actual prevalence. Over half (54%) of TumGard buyers were already on regular antacid or PPI medication and remained symptomatic. 67% had been suffering for more than one year, and 37% for more than three years. Gut dysfunction in India extends far beyond the stomach: 56% report back and joint pain caused by trapped gas, 45% report gas-related headaches, 83% have abnormal stool, and 35% have recurring mouth ulcers alongside digestive symptoms. The data was collected by Hugg Beverages (makers of TumGard) between 2023 and 2026 from Indians actively seeking gut health support.
Source: TumGard India Gut Health Report 2026 by Hugg Beverages. Data collected 2023–2026. Published February 2026. Available at gethugg.com/india-gut-health-report-2026.
Eight numbers that define India's gut health crisis — drawn from 20,363 respondents across TumGard's survey database.
When asked whether they had H. pylori as a chronic condition, only 1.4% of respondents (188 of 13,536) identified it. Yet when TumGard's buyers were asked about their endoscopy results, the picture changed completely.
Of the 1,111 buyers who had undergone endoscopy, 62% came back H. pylori positive. That is not a fringe finding — it is the majority result. Independent clinical studies in India report comparable positivity rates, ranging from 42–90% depending on the patient population.[1][2]
1.4% of Indians with gut symptoms think they have H. pylori. 62% of those who tested came back positive. That is a 44x difference between perceived and actual prevalence. Most Indians with recurring acidity have never been tested — and most who test, test positive.
H. pylori is asymptomatic in most cases — it doesn't announce itself. Its symptoms (acidity, bloating, stomach pain) are identical to dozens of other conditions. Without an endoscopy or breath test, there is no way to know. And 25% of TumGard's buyers had never had a single diagnostic test despite suffering for over a year.
Awareness vs. actual prevalence
| Endoscopy Result | % of those scoped |
|---|---|
| H. pylori positive | 62.0% |
| Gastritis confirmed | 23.9% |
| Hiatal hernia | 4.6% |
| LAX LES (reflux) | 3.0% |
| Normal findings | 5.8% |
25% of TumGard buyers had never had any diagnostic test — despite 62% suffering for over a year. Hundreds of people, medicated and symptomatic, with no diagnosis.
In TumGard's survey of 2,263 Indian adults with gut symptoms, 62% of those who underwent endoscopy tested positive for H. pylori infection — yet only 1.4% of all respondents across 13,536 surveys self-identified as having H. pylori. This represents a 44x gap between perceived and actual prevalence, suggesting that the vast majority of Indians with H. pylori infection do not know they have it.
When acidity is worst (RCA cohort, n=718)
Acidity is not a niche problem for Indian adults. 82% of respondents experience it — and more than a third experience it every single day.
But the more important finding is what happens after people seek help. More than half of TumGard's buyers were already on regular antacid or PPI medication when they first reached out. They were not untreated. They were mistreated — their symptoms were being suppressed, not healed.
38% of TumGard's buyers had been on acidity medication for over a year and were still symptomatic. Medication was controlling acid production — but not addressing the bacterial infection or mucosal damage causing the acid in the first place.
| Duration of Suffering | Respondents |
|---|---|
| Suffering 3+ years | 37.2% (822 buyers) |
| Suffering 1–3 years | 30.1% (664 buyers) |
| Suffering 3–12 months | 20.7% (456 buyers) |
| Suffering 1–3 months | 12.1% (266 buyers) |
Over two-thirds had been dealing with their problem for more than a year. More than a third for over three years — through multiple rounds of medication, diet changes, and home remedies.
TumGard's survey of 13,536 Indians found that 82% experience acidity. Among TumGard's 2,263 buyers, 54% were already on regular antacid or PPI medication — and 38% had been on medication for over a year with symptoms still unresolved — pointing to a systemic gap between symptom suppression and actual healing of the stomach lining.
Among the 1,111 TumGard buyers who had undergone an endoscopy, the two most common findings were H. pylori infection and gastritis. These conditions co-exist frequently — H. pylori is the leading known cause of chronic gastritis. When you see both numbers in the same cohort, you are largely seeing the same patients.
H. pylori causes chronic inflammation of the stomach lining — that inflammation is gastritis. When our data shows 62% H. pylori positivity and 24% confirmed gastritis in the same endoscopy cohort, these are not independent findings. They are two ways of seeing the same underlying problem. A patient diagnosed with antral gastritis very likely has H. pylori. Yet most are only given PPIs — not tested for the bacteria causing the inflammation.
H. pylori is classified as a Group 1 carcinogen — the highest risk category — by the International Agency for Research on Cancer (IARC), a body of the World Health Organisation. It is the only bacterium ever assigned this classification.[3]
Of the 1,111 TumGard buyers who had undergone endoscopy, 62% were H. pylori positive, 24% received a confirmed gastritis diagnosis, and only 5.8% had a fully normal result. Taken together, over 85% of endoscopies in this cohort identified a clinically significant finding.
Stomach pain was the third most common primary complaint among TumGard's buyers, behind only acidity and bloating. Nearly 1 in 5 listed it as their single biggest problem.
What makes this finding significant is not the prevalence — it is the duration. This is not acute pain. This is pain that people have been living with for years, through multiple failed interventions.
The 37% who suffered for over three years had likely tried dietary changes, antacids, prescription medicines, and home remedies. By the time they reached TumGard, conventional approaches had repeatedly failed. That duration is itself a signal that symptom-only treatment doesn't work when the root cause is bacterial infection or mucosal damage.
| Primary Complaint | % of buyers |
|---|---|
| Acidity / heartburn | 37.3% |
| Bloating and gas | 34.7% |
| Stomach pain | 19.7% |
| Unsatisfactory bowel | 6.0% |
What makes stomach pain worse
67% of TumGard's buyers had been suffering from their gut symptoms for over one year, and 37% for over three years — most without resolution despite medication. Stomach pain was the primary complaint for nearly 20% of buyers. Symptoms were consistently worst when eating out, under stress, and in the two hours following a meal.
Full oral symptom picture (n=13,536)
97% of respondents had at least one oral symptom alongside their gut problems.
One of the most striking findings in the entire dataset: 35% of Indians with gut symptoms also have recurring mouth ulcers. Nearly 1 in 3 has both acidity and mouth ulcers at the same time.
And almost nobody has made that connection. Most people treat mouth ulcers topically. Most take antacids for acidity. Very few consider that both problems might share the same root cause.
The stomach lining and the oral mucosa are both mucosal tissues. When the body's mucosal defences are compromised — whether by H. pylori infection, chronic inflammation, or bacterial imbalance — both surfaces can be affected simultaneously. The 27% co-occurrence of acidity and mouth ulcers in our data is not coincidental. It is systemic mucosal weakness presenting in two places at once.
Flavonoids — the active compounds in TumGard — work at the mucosal layer. They support the stomach lining's ability to produce its protective mucus barrier, reduce inflammatory signalling, and create an environment hostile to H. pylori colonisation. The same biological pathway that supports stomach lining health also supports mucosal tissue integrity more broadly — which is why many TumGard users report improvement in mouth ulcer frequency alongside their primary digestive symptoms.
TumGard's survey of 13,536 Indians with digestive symptoms found that 35% also experience recurring mouth ulcers, and 27% reported both acidity and mouth ulcers simultaneously. Only 3% of respondents had no oral symptoms whatsoever — suggesting a shared underlying mechanism rather than independent conditions.
Across two independent survey cohorts (total: 3,406 respondents), we asked what was happening in their lives when gut problems first started. Three patterns emerged with striking consistency.
Someone whose problems began after antibiotics likely has a disrupted microbiome alongside any H. pylori issue. Someone who started experiencing symptoms during a high-stress period may need both mucosal support and stress management. Knowing the trigger is part of knowing the cure — which is why TumGard's assessment process asks about it from the start.
Across two TumGard cohorts (n=3,406), approximately 30% of respondents traced their gut problems to a major stressful life period, 16% to a course of antibiotics or medicines, and 7% to starting night shift work — pointing to identifiable, lifestyle-linked triggers rather than spontaneous onset.
Acidity and bloating are the visible symptoms. But TumGard's data reveals a broader pattern: gut dysfunction in India is causing pain, weight problems, and neurological symptoms that most people never connect to their gut.
Weight impact
| Weight status | Respondents |
|---|---|
| Weight stuck (can't lose) | 29.5% |
| Gaining unexpectedly | 25.5% |
| Losing unexpectedly | 19.7% |
| No weight issue | 25.3% |
75% of respondents — 10,108 of 13,536 — have a weight problem alongside gut symptoms.
When gut fermentation is excessive — as happens with H. pylori overgrowth or compromised digestion — gas accumulates and creates pressure that radiates to the back and joints. The gut-brain axis means gut distress directly impacts neurological signalling, producing headaches, mental fog, and mood changes.[9]
The 56% reporting joint pain from gas and 45% reporting headaches are not describing coincidental symptoms. They are describing the systemic reach of gut dysfunction that medicine routinely treats in isolation.
H. pylori infection directly affects nutrient absorption — particularly iron, B12, and zinc — which disrupts metabolism.[7][8] The 30% of respondents whose weight is stuck despite their efforts may be dealing with a metabolic consequence of unresolved bacterial infection, not a diet or exercise problem.
83% of respondents have abnormal stool — only 1 in 6 forms normal stool. Not formed (43.6%), sticky (26.9%), and dry/hard (12.8%) are the three dominant patterns. Each tells a different story about gut microbiome health, hydration, and digestive enzyme function.
TumGard's data from 13,536 respondents found that gut problems extend well beyond the stomach: 56% reported back and joint pain from trapped gas, 45% reported gas-related headaches, and 83% had abnormal stool. Additionally, 75% reported a weight problem alongside their digestive symptoms — suggesting that gut dysfunction in India is significantly underestimated as a whole-body health issue.
According to TumGard's survey of 13,536 Indians with digestive symptoms, 82% experience acidity or heartburn. 38% experience it every single day. Over half (54%) were already on regular antacid or PPI medication and still symptomatic — suggesting the majority are managing symptoms without treating the root cause.
In TumGard's database, 62% of Indians who underwent endoscopy tested positive for H. pylori infection. Yet only 1.4% of all surveyed respondents self-identified as having H. pylori — a 44x gap between actual and perceived prevalence. Most Indians with H. pylori infection do not know they have it because the symptoms are identical to ordinary acidity or gastritis.
54% of TumGard buyers were already on regular acidity medication before seeking help — and still had unresolved symptoms. Antacids and PPIs suppress acid production but do not treat the underlying bacterial infection (H. pylori) or repair the damaged stomach lining. Recurrence is common because the root cause goes untreated. 38% had been on medication for over a year with no lasting relief.
Yes. TumGard's data from 13,536 Indians found that 56% reported back and joint pain caused by trapped gas, and 45% reported gas-related headaches. Excessive gut fermentation creates pressure that radiates to the back and joints. The gut-brain axis means gut distress also directly impacts neurological signalling, producing headaches and mental fog.
TumGard's data found that 35% of Indians with digestive symptoms also have recurring mouth ulcers, and 27% reported both acidity and mouth ulcers simultaneously. The stomach lining and oral mucosa are both mucosal tissues — when mucosal defences are compromised by H. pylori or chronic inflammation, both surfaces can be affected at once. Only 3% of respondents had no oral symptoms whatsoever.
67% of TumGard buyers had been suffering for more than one year before seeking a different approach. 37% had suffered for over three years. Most had tried dietary changes, antacids, and prescription medication without lasting relief. The long duration suggests that standard treatments address symptoms but not the underlying cause.
TumGard's findings are contextualised against the following peer-reviewed and institutional sources. Each citation is mapped to a specific claim in this report.
TumGard is India's only flavonoid-based gut jam formulated to create an environment hostile to H. pylori and support your stomach lining's natural defences.
This report presents findings from TumGard's proprietary gut health survey database — collected via five digital assessment instruments between 2023 and early 2026. All 20,363 respondents voluntarily completed the assessments as part of TumGard's personalised gut health programme. Respondents self-selected by seeking gut health support; prevalence figures reflect Indians actively managing digestive symptoms and should not be extrapolated as population-level estimates.
The endoscopy data (H. pylori positivity, gastritis findings) is drawn from the TumGard Digestion Analysis quiz (n=2,263), specifically from the 1,111 respondents who self-reported having undergone an endoscopy. This is self-reported clinical history. Median respondent age: 34 years. 72% under 40. Pan-India distribution.
To cite this report: Raj, M.A. (RD, IDA Reg. 013/2011) & Doshi, H. TumGard India Gut Health Report 2026. Hugg Beverages Pvt. Ltd. February 2026. Available at: gethugg.com/india-gut-health-report-2026